Mercado Global de Sirolimus – Tendências da Indústria e Previsão para 2031

Análise e dimensão do mercado de sirolimus

Prevê-se que o mercado do sirolimus cresça rapidamente durante o período de previsão. De acordo com a Organização Mundial de Saúde (OMS), são realizados cerca de 100.800 transplantes de órgãos sólidos em todo o mundo a cada ano, sendo 69.400 transplantes renais, 20.200 transplantes hepáticos, 5.400 transplantes cardíacos, 3.400 transplantes pulmonares e 2.400 transplantes de pâncreas os mais comuns. A crescente taxa de transplantes e o aparecimento de doenças relacionadas com o estilo de vida são os principais fatores que levam à elevada procura do sirolimus no mercado.  

A Data Bridge Market Research analisa que o mercado global de sirolimus, que foi de 280,13 milhões de dólares em 2023, deverá atingir os 424,23 milhões de dólares até 2031, e deverá passar por um CAGR de 4,6% durante o período de previsão de 2024 a 2031. “0,5 mg ”Domina o segmento de força do mercado devido à crescente procura de sirolimus. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado sirolimus

Definição de mercado

O sirolimus, vulgarmente conhecido como rapamicina, é uma molécula macrólido que é um forte imunossupressor com atividades antifúngicas e anticancerígenas. Atua suprimindo o sistema imunitário e ajudando o organismo a aceitar o novo órgão, reduzindo assim a rejeição de órgãos após o transplante. O sirolimus é também utilizado para revestir stents coronários, bem como para tratar a linfangioleiomiomatose (doença pulmonar) e para prevenir a rejeição de transplantes de órgãos em doentes submetidos a transplantes renais.

Dinâmica global do mercado do sirolimus

Motoristas

• Aumento dos transplantes de órgãos

O número crescente de procedimentos de transplante de órgãos em todo o mundo aumentou significativamente a procura de Sirolimus. É amplamente utilizado como imunossupressor para prevenir a rejeição em recetores de transplantes de órgãos. O aumento da procura é atribuído aos avanços nas técnicas cirúrgicas, ao aumento da consciencialização sobre a doação de órgãos e à melhoria dos cuidados pós-transplante.

• Expandindo as Aplicações em Oncologia

O sirolimus exibe propriedades antitumorais e é empregue no tratamento de vários tipos de cancro, incluindo o carcinoma de células renais. Esta aplicação em oncologia tem vindo a ganhar atenção devido à sua capacidade de inibir o alvo da rapamicina em mamíferos (mTOR), uma proteína associada à proliferação de células cancerígenas. Estudos clínicos que exploram a eficácia do Sirolimus em diferentes tipos de cancro continuam a alimentar a sua utilização em tratamentos oncológicos.

• Avanços nos stents farmacológicos

Os stents revestidos com sirolimus desempenham um papel crucial na cardiologia de intervenção, reduzindo as taxas de reestenose após angioplastia. Estes stents farmacológicos demonstraram uma eficácia superior em comparação com os stents convencionais. Os avanços contínuos na tecnologia de stents, incluindo o desenvolvimento de stents farmacológicos de última geração, contribuem para o crescimento do mercado.

Oportunidades

• Aumento da procura por medicamentos personalizados

A mudança de paradigma para a medicina personalizada apresenta uma oportunidade significativa para o Sirolimus. A adaptação dos tratamentos com base na composição genética dos doentes, nas características da doença e nas respostas individuais à terapêutica oferece formas de otimizar a posologia e os regimes de tratamento do Sirolimus .

• Mercados emergentes e regiões inexploradas

Expanding into emerging markets and regions with unmet medical needs provides growth opportunities. Targeting regions witnessing a rise in organ transplantation rates or an increasing prevalence of cancers where Sirolimus can offer therapeutic benefits is a strategic opportunity.

Restraints/Challenges

• Adverse Effects and Safety Concerns

Sirolimus usage is associated with adverse effects such as immunosuppression-related complications, increased susceptibility to infections, metabolic disturbances, and delayed wound healing. Managing these adverse effects and ensuring patient safety pose significant challenges, particularly in long-term therapy.

• Regulatory Hurdles and Compliance

Regulatory approvals for pharmaceuticals, particularly for immunosuppressant like Sirolimus, involve stringent assessments of safety and efficacy. Meeting these stringent standards, especially in different regions with varying regulatory frameworks, can delay product launches and market entry.

This sirolimus market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the sirolimus market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

• In November 2021, for adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumors, the Food and Drug Administration licensed sirolimus protein-bound particles for injectable suspension (albumin-bound). Efficacy was assessed in 31 patients with locally advanced unresectable or metastatic malignant PEComa in the AMPECT (NCT02494570) multicenter, single-arm clinical study. Until disease progression or unacceptable toxicity, patients received 100 mg/m2 sirolimus protein-bound particles on days 1 and 8 of each 21-day cycle

Global Sirolimus Market Scope

The sirolimus market is segmented on the basis of strength, application, dosage, drug class, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Strength

• 0.5mg
• 1mg
• 2mg
• 1mg/mL

Application

• Organ Transplant Rejection
• Sirolimus Catheter Device
• Sirolimus Coated Balloons
• Others

Drug Class

• MTOR Inhibitors
• Selective Immunosuppressants

Dosage

• Injection
• Tablet
• Others

Route of Administration

• Oral
• Intravenous
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Global Sirolimus Market Regional Analysis/Insights

The sirolimus market is analyzed and market size insights and trends are provided by country, strength, application, dosage, drug class, route of administration, end-users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the market due of the increase in the expenditure for research and development proficiencies, increasing government’s initiatives and improved health care infrastructure in various countries.

Asia-Pacific is expected to exhibit the highest growth rate in the market during the forecast period of 2024 to 2031 due to the increasing government expenditure on healthcare sector and rising technological advancements and initiatives by the government.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Sirolimus Market Share Analysis

The sirolimus market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to sirolimus market.

Some of the major players operating in the sirolimus market are:

• Accord Healthcare (U.S.)
• Apotex Inc. (Canada)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc. (U.S.)
• Zydus Cadila (India)
• Dr. Reddy's Laboratories Ltd. (India)
• Torrent Pharmaceuticals Ltd. (India)
• Biocon (India)
• Concept Medical (U.S.)
• Intas Pharmaceuticals Ltd (India)
• Concord Biotech (India)
• Livzon (China)
• Actiza Pharmaceutical Private Limited (India)
• Tiefenbacher API + Ingredients GmbH & Co. KG (Germany)
• Delphis Pharmaceutical (India)

SKU-53419